Clinical Study to Evaluate the Drug-Drug Interaction and Safety of Telmisartan, Amlodipine and/or Chlorthalidone in Healthy Adult Volunteers
- Conditions
- Diseases of the circulatory system
- Registration Number
- KCT0001172
- Lead Sponsor
- Yuhan
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Active, not recruiting
- Sex
- All
- Target Recruitment
- 60
1.Participant who has a body weight that is >=55kg(male) or >=50kg(female) with ideal bosy weight of 80-120%
2.Who has not suffered from clinically significant disease
3.Provision of signed written informed consent
1.History of and clinically significant disease
2.A history of drug abuse or the presence of positive reactions to drugs that have abuse potential in urine screenings for drugs
3.Administration of other investigational products within 3 months prior to the first dosing.
4.Administration of herbal medicine within 2 weeks or administration of ethical drugs within 2 weeks or administration of over-the-counter (OTC) drugs within 1 week prior to the first dosing of the investigational product (if the investigator (study doctor) determines that the person meets other criteria appropriately, the relevant person may participate in the study).
5.Volunteers considered not eligible for the clinical trial by the investigator (study doctor) due to reasons including laboratory test results, ECGs, or vital signs.
Study & Design
- Study Type
- Interventional Study
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method